Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report?
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards?
Catalyst Pharmaceutical (CPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable
Strength Seen in Catalyst (CPRX): Can Its 6.7% Jump Turn into More Strength?
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Head-To-Head Survey: Aptorum Group (NASDAQ:APM) versus Catalyst Pharmaceuticals (NASDAQ:CPRX)
Does Catalyst (CPRX) Have the Potential to Rally 28.87% as Wall Street Analysts Expect?
See How Institutions Boost Catalyst Shares
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
CPRX or UTHR: Which Is the Better Value Stock Right Now?
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
New Strong Buy Stocks for March 31st
Best Value Stocks to Buy for March 31st
Wall Street Analysts Predict a 45.3% Upside in Catalyst (CPRX): Here's What You Should Know
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
CPRX vs. UTHR: Which Stock Is the Better Value Option?
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks
Choreo LLC Buys Shares of 20,895 Catalyst Pharmaceuticals, Inc. $CPRX
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34%